Abstract: Apparatus and methods provide anti-spoofing capability from a first global navigation satellite system (GNSS) receiver to a second GNSS receiver. These GNSS receivers can be, for example, global positioning satellite (GPS) receivers. Via an authentication technique, signals from authentic GNSS sources are distinguished from signals from spoofers. Timing information, such as numerically-controlled oscillator (NCO) settings, used for tracking authenticated signals are then used to generate replica GNSS signals, which are then provided to the second GNSS receiver. As a result, the second GNSS receiver can provide accurate positioning system information in the presence of GNSS spoofers.

Abstract: The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more PSA-derived peptides, and their use to treat or prevent prostate cancer in the patient. The invention is also directed to T-cells from a patient which cells are specific for PSA-activated peptide(s), and their uses to treat or prevent prostate cancer.

Abstract: The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more PSA-derived peptides, and their use to treat or prevent prostate cancer in the patient. The invention is also directed to T-cells from a patient which cells are specific for PSA-activated peptide(s), and their uses to treat or prevent prostate cancer.

Abstract: A nucleic acid molecule comprising at least one nucleotide sequence encoding SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a polypeptide consisting of SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a composition comprising APC, which have been exposed to the polypeptide, and a method of administering same to treat prostate cancer; a composition comprising T-cells, which are specific for an epitope in a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; a composition comprising an anti-idiotypic antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; and an immortal B-c

Abstract: The present invention provides a superior method of diagnosing Chronic Pelvic Pain Syndrome in men comprising measuring levels of cytokines in semen or components or fractions of semen. The invention also provides a method of treating a condition associated with elevated levels of a cytokine, such as TNF-&agr;, in semen or a component or fraction thereof, comprising administering a therapeutically effective amount of an ant-cytokine compound or composition, such as an anti-TNF-&agr; compound or composition.

Abstract: The characteristic voltage-versus-time curve for a nickel-cadmium battery on a fast charge, e.g., being charged at the C/1 rate, increases to a peak voltage and thereafter decreases. To ensure that the battery is fully charged, the fast charge is discontinued on the decreasing portion of the voltage-versus-time curve. The fast charge may be stopped when a predetermined negative rate of change of the voltage is obtained. Or the fast charge may be cut off when the battery voltage decreases a predetermined amount below the peak, that is, when the difference between the maximum measured battery voltage and the present battery voltage exceeds a setpoint. After the fast charge is discontinued, a trickle charge, e.g., a C/10 charge or less, may be instituted or the charging current may be interrupted altogether, i.e., the battery charging circuit may be opened.